murin
antisera
neutralis
activ
coronaviru
caus
middl
east
respiratori
syndrom
mer
induc
immunis
balbc
mice
receptor
bind
domain
rbd
viral
spike
protein
murin
antisera
induc
fullyneutralis
vitro
two
separ
clinic
strain
mer
coronaviru
merscov
test
neutralis
capac
antisera
vivo
suscept
merscov
induc
naiv
recipi
balbc
mice
administr
adenoviru
vector
express
human
receptor
merscov
prior
passiv
transfer
rbdspecif
murin
antisera
transduc
mice
subsequ
challeng
recipi
transduc
mice
intranas
rout
clinic
isol
merscov
result
significantli
reduc
viral
load
lung
compar
transduc
mice
receiv
neg
control
antibodi
murin
antisera
use
deriv
mice
prime
subcutan
recombin
fusion
rbd
human
igg
fc
tag
rbdfc
adsorb
calcium
phosphat
microcryst
boost
oral
rout
fusion
protein
revers
micel
data
gain
indic
dualrout
vaccin
novel
formul
rbdfc
induc
system
mucos
antivir
immun
demonstr
vitro
vivo
neutralis
capac
clinic
strain
merscov
crown
middl
east
respiratori
diseas
syndrom
mer
first
emerg
saudi
arabia
sinc
estim
laboratoryconfirm
case
death
report
total
countri
eastern
mediterranean
region
countri
elsewher
saudi
arabia
howev
remain
main
focu
infect
diseas
outbreak
south
korea
involv
case
trace
back
index
case
travel
saudi
arabia
whilst
incid
mer
case
saudi
arabia
peak
still
signific
number
case
report
countri
period
septemb
case
includ
death
case
fatal
rate
mer
coronaviru
merscov
member
betacoronaviru
genu
betacoronavirus
bat
may
provid
natur
reservoir
viru
high
level
antibodi
merscov
dromedari
camel
suggest
dromedari
camel
princip
sourc
animaltohuman
transmiss
merscov
howev
evid
humantohuman
transmiss
come
report
outbreak
countri
remot
saudi
arabia
uk
europ
usa
china
small
outbreak
also
occur
merscov
envelop
positivesens
singlestrand
rna
viru
viru
possess
envelopeanchor
trimer
spike
protein
bind
human
receptor
dipeptidyl
peptidas
gain
host
cell
entri
fusion
viral
host
membran
spike
protein
compris
subunit
membran
fusion
subunit
coronavirus
subunit
divid
ntermin
ctermin
subdomain
merscov
ctermin
subdomain
compris
receptorbind
domain
rbd
rbd
also
incorpor
receptorbind
motif
ctermin
crystal
structur
merscov
rbd
rbd
bound
extracellular
domain
human
report
rbd
coronavirus
repres
vaccin
therapeut
target
rbd
merscov
vaccin
antigen
demonstr
induc
neutralis
antibodi
protect
mice
transduc
viral
vector
express
nonhuman
primat
viral
challeng
signific
ongo
effort
develop
vaccin
merscov
infect
predominantli
involv
live
attenu
viral
vector
adenoviru
modifi
vaccinia
ankara
measl
induc
antivir
immun
vaccin
alreadi
clinic
trial
interest
determin
rel
import
induc
system
andor
mucos
immun
vaccin
protect
merscov
infect
predominantli
respiratori
tract
lung
end
use
dual
rout
immunis
regimen
balbc
mice
induc
system
mucos
immun
gener
rbdspecif
murin
antisera
initi
immunis
balbc
mice
subcutan
sc
rbdfc
adjuv
induc
rbdspecif
igg
subsequ
immunis
group
balbc
mice
sc
prime
per
oral
po
boost
rbdfc
induc
system
igg
mucos
iga
respons
use
novel
formul
rbdfc
coat
onto
microcryst
form
histidin
glutamin
also
incorpor
calcium
phosphat
subcutan
prime
whilst
formul
oral
boost
compris
rbdfc
revers
micel
dispers
selfemulsifi
oil
phase
optimis
previou
formul
advantag
formul
stabl
extrem
temperatur
furthermor
translat
clinic
one
inject
prime
dose
would
requir
follow
po
booster
dose
latter
could
selfadminist
capsul
form
compar
rel
abil
two
sourc
antiserum
neutralis
clinic
isol
merscov
vitro
use
two
clinic
strain
merscov
erasmu
medic
center
deriv
severelyil
individu
contract
viru
middl
east
subsequ
sequenc
polymeras
gene
isol
indic
newlyemerg
member
betacoronaviru
genu
close
sequenc
homolog
phylogenet
relationship
bat
coronavirus
mice
natur
suscept
merscov
infect
suscept
induc
administr
adenoviru
vector
induc
express
human
receptor
viru
vivo
limit
time
provid
nonleth
murin
model
diseas
use
transduc
mous
model
test
capac
antiserum
deriv
dual
rout
immunis
neutralis
merscov
vivo
passiv
transfer
prior
challeng
strain
demonstr
signific
reduct
viral
load
lung
tissu
transduc
mice
rbd
synthesis
express
accord
method
adapt
du
et
al
brief
singl
dna
fragment
contain
infram
fusion
code
sequenc
human
signal
peptid
rbd
human
synthesis
transfer
plasmid
invitrogen
target
sequenc
express
secret
protein
ctermin
human
fc
tag
construct
transfect
cation
transfect
human
embryo
kidney
hek
cell
suspens
fshek
adher
hek
cell
stabli
express
larg
antigen
use
serumfre
media
incub
day
small
scale
purif
rbdfc
perform
use
protein
chromatographi
medium
transfect
cell
treat
ammonium
sulphat
precipit
protein
prior
dialysi
resuspens
buffer
bind
protein
bead
latter
wash
elut
buffer
contain
urea
protein
concentr
determin
uv
absorb
spectroscopi
puriti
estim
sdspage
coomassi
stain
subsequ
optic
densitometri
use
syngen
g
box
imag
system
rbdfc
incorpor
glutamin
calcium
phosphat
cap
microcryst
sc
immunis
use
methodolog
adapt
briefli
aqueou
mixtur
rbdfc
sodium
orthophosph
glutamin
precipit
cap
proteinco
microcryst
cappcmc
addit
excess
isopropanol
contain
dissolv
calcium
chlorid
result
suspens
contain
selfassembl
microcryst
compris
glutamin
core
rbdfc
protein
embed
thin
surfac
layer
cap
term
rbdfcpcmc
pcmc
isol
vacuum
filtrat
dri
powder
protein
content
integr
determin
elisa
sdspage
oral
dose
rbdfc
incorpor
miner
oil
ad
excipi
use
methodolog
adapt
oral
formul
compris
rbdfc
mucos
adjuv
cholera
toxin
b
subunit
ctb
retino
acid
ra
vitamin
e
trehalos
debehen
tdb
synthet
analog
mycobacteri
trehalos
dimycol
imiquimod
tlr
agonist
specif
pathogenfre
femal
balbc
mice
week
age
obtain
commerci
breeder
use
throughout
studi
receipt
mice
randomis
alloc
cage
given
free
access
food
water
environment
enrich
mice
fulli
acclimatis
anim
hous
facil
least
five
day
prior
procedur
anim
procedur
perform
accord
uk
legisl
state
uk
anim
scientif
procedur
act
institut
anim
care
use
committe
approv
relev
project
licenc
mice
randomis
alloc
treatment
group
typic
per
group
immunis
one
two
regimen
either
sc
prime
dose
follow
two
sc
dose
given
day
prime
altern
mice
receiv
sc
prime
dose
follow
oral
sc
booster
dose
day
prime
tabl
sc
immunis
mice
receiv
lg
rbdfcpcmc
ml
pb
inject
volum
wherea
per
oral
po
dose
mice
receiv
lg
rbdfc
total
volum
ml
miner
oil
mo
oral
gavag
rbdfc
administ
sc
convent
adjuv
alhydrogel
novarti
us
use
ratio
volum
rbdfc
pb
whilst
alhydrogel
brenntag
biosector
denmark
use
ratio
rbdfc
volum
pb
select
interv
dose
mice
bloodsampl
tail
vein
assay
specif
antibodi
titr
end
immunis
schedul
individu
mice
termin
anaesthetis
collect
blood
cardiac
punctur
cull
prior
remov
small
larg
intestin
collect
faecal
pellet
extract
iga
titr
rbdfcspecif
antibodi
serum
sampl
determin
elisa
brief
test
sera
bound
microtitr
plate
precoat
rbdfc
antibodi
bind
detect
hrpolabel
secondari
antibodi
mous
igg
iga
biorad
standard
curv
calibr
compris
relev
murin
ig
isotyp
sigma
captur
antifab
reagent
includ
plate
plate
develop
addit
azinobi
acid
diammonium
salt
abt
substrat
sigma
optic
densiti
od
read
nm
multiskan
plate
reader
assay
antibodi
faecal
sampl
faecal
pellet
extract
supplement
pb
describ
previous
brief
ml
cold
pb
prepar
supplement
tablet
complet
mini
proteas
inhibitor
cocktail
sigma
tween
ad
g
faecal
pellet
ml
supplement
pb
ad
left
room
temperatur
min
sampl
vortex
approxim
incub
ice
min
centrifug
min
supernat
retain
store
pend
assay
faecal
extract
assay
specif
igg
iga
content
elisa
serum
sampl
antibodi
concentr
sampl
determin
relev
standard
curv
use
ascent
softwar
fourparamet
logist
curvefit
report
ngml
lgml
serum
faecal
extract
appropri
determin
antibodi
induc
immunis
rbdfc
neutralis
merscov
vitro
plaqu
assay
perform
two
strain
merscov
use
genbank
access
number
erasmu
medic
center
genbank
access
number
strain
obtain
nation
collect
pathogen
virus
phe
porton
salisburi
uk
strain
kindli
provid
erasmu
univers
medic
center
rotterdam
netherland
strain
prepar
serumfre
media
gibco
multipl
infect
moi
equival
plaqueform
unit
pfu
murin
antiserum
test
prepar
dilut
rang
undilut
pb
viru
incub
overnight
murin
antiserum
neg
control
antibodi
nibsc
uk
media
prior
infect
confluent
monolay
vero
cell
ecacc
salisburi
uk
mixtur
neutralis
abil
murin
antiserum
test
duplic
triplic
dilut
incub
h
overlay
compris
dilut
carboxymethyl
cellulos
serumfre
media
ad
cell
incub
continu
day
prior
fix
formaldehyd
stain
crystal
violet
enumer
number
plaqu
per
ml
mice
natur
suscept
infect
merscov
sinc
lack
human
receptor
induc
transient
suscept
balbc
mice
use
construct
oxford
genet
express
human
receptor
previous
describ
mice
administ
construct
pfu
intranas
rout
light
sedat
inhal
isofluoran
monitor
serial
blood
sampl
serum
level
elisa
thermoscientif
peak
level
express
day
mice
lightli
sedat
challeng
rout
merscov
strain
pfu
per
mous
mice
weigh
prior
challeng
subsequ
day
monitor
chang
bodi
weight
infect
test
vivo
neutralis
capac
murin
antiserum
rais
rbdfc
construct
mice
n
per
treatment
group
passiv
immunis
ip
rout
h
prior
challeng
mer
cov
strain
describ
murin
antiserum
pool
mice
prime
rbdfc
pcmc
boost
oral
regimen
treatment
group
deliv
dilut
pb
deliv
total
volum
per
mous
group
mice
receiv
purifi
polyclon
human
igg
singl
dose
level
lgmous
ip
rais
inactiv
merscov
control
mice
receiv
nonspecif
human
igg
singl
doselevel
lgmous
ip
set
human
igg
specif
nonspecif
rais
bovin
transchromosom
model
purifi
prior
use
group
neg
control
mice
includ
receiv
pb
place
either
construct
merscovspecif
antibodi
also
challeng
merscov
strain
pfumous
determin
protect
afford
passiv
immunis
pair
mice
treatment
group
cull
day
challeng
lung
remov
weigh
rapidli
frozen
prior
determin
viral
load
pair
lung
mice
per
treatment
group
individu
thaw
homogenis
serumfre
media
ml
rna
extract
homogen
use
qiaamp
viral
rna
kit
qiagen
follow
manufactur
instruct
realtim
pcr
conduct
duplic
amount
viru
test
sampl
determin
duplic
use
standard
curv
report
pfug
lung
tissu
data
analys
use
graph
pad
prism
softwar
express
mean
sem
statist
comparison
made
use
oneway
anova
unpair
ttest
rbdfc
protein
express
adher
suspens
human
embryo
kidney
hek
cell
greater
express
adher
cell
fig
purif
protein
adher
cell
protein
effect
yield
protein
pure
molecular
weight
approxim
kda
fig
use
urea
elut
optimum
suffici
solubilis
protein
without
denatur
yield
rbdfc
optimum
yield
mgml
predominantli
dimer
form
fig
method
protein
purif
therefor
select
forward
use
rbdfc
formul
either
subcutan
sc
per
oral
po
immunis
test
immunogen
formul
optimis
iter
approach
initi
sc
dose
regimen
use
rbdfc
formul
either
alhydrogel
deliv
lg
protein
three
occas
day
mice
monitor
day
final
boost
igg
titr
determin
fig
day
total
igg
titr
achiev
rbdfc
alhydrogel
differ
significantli
determin
present
rbdfc
either
alhydrogel
influenc
abil
develop
virusneutralis
antibodi
antisera
select
mice
immunis
group
test
plaqu
assay
neutralis
strain
merscov
fig
c
four
sera
gave
neutralis
viral
activ
although
dilut
sera
potent
viral
strain
sera
deriv
treatment
group
immunis
rbdfc
wherea
sera
deriv
alhydrogeladjuv
rbdfc
fig
base
pilot
data
subsequ
use
convent
adjuv
rbdfc
compar
novel
formul
demonstr
proofofprincipl
rbdfc
deliv
induc
high
titr
antibodi
neutralis
activ
next
investig
tailor
rbdfc
vaccin
optim
induc
system
mucos
immun
aim
also
reduc
immunis
regimen
increas
function
antibodi
select
novel
formul
rbdfc
protein
present
rbdfcpcmc
sc
prime
incorpor
miner
oil
mo
po
boost
compar
serum
igg
respons
achiev
dual
rout
immunis
induc
rbdfc
deliv
sc
regimen
fig
month
booster
dose
day
signific
differ
serum
igg
titr
achiev
dualrout
immunis
rbdfcpcmc
sc
prime
incorpor
mo
excipi
po
boost
immunogen
sc
immunis
rbdfc
fig
day
serum
respons
rbdfc
dualrout
regimen
predominantli
bias
wherea
sc
dose
rbdfc
presenc
induc
fig
sinc
dual
rout
immunis
effect
induc
serum
igg
rbdfc
interest
determin
whether
could
also
effect
induc
mucos
immun
studi
rbdfcspecif
iga
respons
determin
serum
faecal
pellet
extract
individu
anim
day
case
rbdspecif
iga
respons
mice
immunis
dual
rout
regimen
compar
mice
immunis
oral
rout
twice
mice
immunis
sc
rout
twice
exactli
day
fig
comparison
show
sc
immunis
induc
serum
iga
howev
sc
prime
rbdfcpcmc
po
boost
effect
induc
rbdfcspecif
iga
inferior
oral
prime
boost
effect
either
serum
fig
faecal
extract
fig
howev
mice
prime
boost
oral
develop
rbdspecif
system
igg
data
shown
addit
day
sera
mice
treatment
group
test
abil
neutralis
either
strain
merscov
vitro
tabl
seen
sera
mice
dual
rout
regimen
fulli
neutralis
neutralis
merscov
vitro
vitro
strain
test
dilut
fig
b
order
test
whether
vitro
neutralis
activ
translat
viral
neutralis
vivo
sera
mice
highlight
tabl
pool
equal
aliquot
dilut
enabl
subsequ
passiv
transfer
studi
order
design
passiv
transfer
studi
necessari
defin
durat
express
murin
lung
vivo
follow
induct
construct
mice
dose
cull
pair
lung
homogen
prepar
assay
express
lung
tissu
express
timedepend
manner
level
peak
day
declin
day
fig
set
suffici
window
use
model
determin
protect
viral
challeng
afford
passiv
transfer
mersspecif
antibodi
determin
protect
afford
passiv
transfer
murin
antiserum
rais
dual
rout
immunis
regimen
infect
suscept
merscov
induc
administr
group
mice
passiv
transfer
ip
rout
pool
serum
sampl
deriv
mice
highlight
tabl
previous
shown
neutralis
vitro
tabl
conduct
day
later
mice
challeng
h
merscov
addit
group
mice
transduc
passiv
immunis
merscov
specif
human
igg
nonspecif
human
igg
day
challeng
pair
mice
cull
determin
viral
load
lung
determin
peak
day
pi
data
shown
day
pi
pool
murin
antiserum
significantli
reduc
viral
titr
lung
extent
specif
human
igg
contrast
neg
control
human
igg
demonstr
signific
vivo
neutralis
activ
fig
fig
express
induc
lung
tissu
administr
pfu
mice
rout
subsequ
mice
cull
pair
day
shown
lung
assay
express
plot
show
timecours
express
day
postinduct
data
point
normalis
background
valu
control
mice
content
merscov
strain
murin
lung
pfug
tissu
determin
rtpcr
day
postinfect
equival
day
passiv
transfer
murin
antisera
rbdfc
previous
shown
neutralis
strain
vitro
mice
receiv
either
merscovspecif
human
igg
lg
nonspecif
human
igg
lg
mous
ip
murin
antisera
rbdfc
pool
murin
donor
deliv
dilut
llmous
ip
neg
control
mice
receiv
pb
place
antiserum
mice
challeng
merscov
pfumous
statist
signific
determin
p
level
one
way
anova
unpair
ttest
signific
differ
bodi
weight
detect
treatment
group
challeng
merscov
attribut
short
time
period
studi
mer
seriou
endem
respiratori
infecti
diseas
licens
vaccin
although
sever
vaccin
clinic
trial
current
includ
adenovirusvector
deliveri
spike
protein
subunit
dna
vaccin
nanoparticledeliv
subunit
approach
interest
determin
advantag
r
vaccin
could
induc
mucos
well
specif
system
immun
key
target
rbd
protein
order
achiev
optimum
protect
efficaci
vaccin
induc
effect
immun
mucos
surfac
prime
immun
system
respond
rapidli
invad
pathogen
merscov
previou
studi
use
adenoviru
deliveri
mer
spike
protein
intramuscular
im
intragastr
ig
deliveri
induc
neutralis
system
igg
iga
whilst
im
deliveri
also
induc
specif
tcell
immun
ig
deliveri
other
shown
intranas
deliveri
live
attenu
adenovirusvector
subunit
vaccin
induc
specif
mucos
well
system
immun
although
translat
approach
clinic
may
rais
safeti
issu
reli
novel
formul
subunit
protein
enabl
dual
rout
vaccin
parenter
oral
induc
mucos
well
system
immun
studi
achiev
express
purif
recombin
rbdfc
protein
milligram
quantiti
also
demonstr
formul
subunit
vaccin
construct
induc
murin
antibodi
effect
neutralis
two
differ
clinic
strain
merscov
vitro
addit
shown
murin
antisera
passiv
transfer
mice
transduc
express
receptor
confer
protect
viral
challeng
recipi
significantli
reduc
viral
load
lung
tissu
recipi
mice
whilst
use
convent
adjuv
alhydrogel
formul
rbdfc
protein
result
high
titr
specif
igg
serum
formul
induc
specif
iga
serum
order
promot
system
mucos
immun
rbdfc
formul
protein
inject
prime
po
boost
entail
optimis
cap
pcmc
revers
micel
oil
emuls
respect
enabl
achiev
vaccin
regimen
compris
two
dose
rapidli
induc
rbdfcspecif
system
mucos
immun
whilst
pcmc
formul
rbdfc
effect
rbd
induc
primari
igg
respons
shown
oral
formul
rbdfc
miner
oil
select
immunostimul
effect
use
booster
immunis
addit
shown
noninvas
oral
prime
boost
effect
induc
specif
mucos
respons
measur
specif
iga
serum
faec
inject
prime
rbdfc
pcmc
formul
togeth
oral
boost
lead
excit
concept
potenti
orallydos
subunit
vaccin
mer
whilst
alhydrogel
combin
pcmc
oral
formul
evidenc
predominantli
titr
rais
rbdfc
influenc
respons
rbdfc
mix
effect
signific
induct
specif
counter
viral
infect
would
expect
respons
would
appropri
howev
fact
neutralis
antibodi
rbdfc
rais
either
influenc
suggest
either
isotyp
protect
prime
immun
system
suffici
would
allow
crosspresent
occur
subsequ
exposur
viru
studi
examin
induct
cellmedi
memori
respons
rbdfc
protein
although
play
signific
role
protect
viru
current
present
rbd
protein
formul
fc
tag
deriv
human
use
purifi
protein
fc
tag
may
contribut
addit
adjuvantis
activ
engag
antigenpres
cell
vaccine
may
aid
mucos
immun
sinc
fc
receptor
transmembran
protein
also
express
mucos
surfac
eg
respiratori
tract
vaccin
zoonot
host
dromedari
camel
may
also
effect
curb
outbreak
mer
endem
region
limit
risk
viral
recombin
signific
progress
orthopoxvector
vaccin
mer
recent
report
potenti
use
subunit
vaccin
mer
camel
vaccin
could
aid
vari
sequenc
rbd
protein
substitut
human
fc
tag
altern
tag
recognis
camel
design
approach
tailor
anim
vaccin
bear
mind
singl
dose
vaccin
would
ideal
context
howev
futur
work
laboratori
also
address
valu
retain
remov
fc
tag
rbd
protein
clinic
veterinari
iter
vaccin
studi
determin
vaccin
efficaci
demonstr
vitro
vivo
neutralis
abil
murin
antisera
rais
dual
rout
twodos
regimen
two
virul
clinic
strain
merscov
greater
genom
sequenc
homologyy
futur
work
worthwhil
test
efficaci
approach
clinic
isol
merscov
first
report
dual
rout
dose
regimen
appli
subunit
vaccin
merscov
futur
develop
approach
would
requir
direct
test
efficaci
immunis
transduc
mous
model
well
give
direct
readout
vaccin
efficaci
enabl
identif
immun
correl
protect
readi
transit
candid
vaccin
extens
preclin
test
clinic
develop
author
declar
data
support
find
studi
avail
within
paper
